Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich, Domainex Partner on Epigenetics

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – UK Contract research organization Domainex and Sigma-Aldrich today announced a collaboration to develop tools for epigenetic research.

Under the deal, Domainex will use its proprietary Combinatorial Domain Hunting technology to clone and express proteins to build biochemical assays for target enzymes. The technology, the company said in a statement, allows researchers to clone and express challenging proteins, producing soluble domains of proteins with key roles in epigenetics.

Sigma-Aldrich will use the proteins as antigens to raise specific monoclonal antibodies. It will also distribute the assays and monoclonal antibodies, which scientists can use to identify target proteins, and then characterize and study their functions in detail.

Funding from the UK's Technology Strategy Board will support the work. Financial and other terms were not disclosed.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.